Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 501

1.

Male breast cancer: immunohistochemical subtypes and clinical outcome characterization.

Sánchez-Muñoz A, Román-Jobacho A, Pérez-Villa L, Sánchez-Rovira P, Miramón J, Pérez D, Sáez MI, de Luque V, Medina L, Ramírez-Tortosa CL, Vicioso L, Medina JA, Ribelles N, Alba E.

Oncology. 2012;83(4):228-33. doi: 10.1159/000341537. Epub 2012 Aug 16.

PMID:
22907070
2.

Breast cancer subtypes identified by the ER, PR and HER-2 status in Thai women.

Chuthapisith S, Permsapaya W, Warnnissorn M, Akewanlop C, Sirivatanauksorn V, Prasarttong Osoth P.

Asian Pac J Cancer Prev. 2012;13(2):459-62.

3.

A retrospective study of breast cancer subtypes: the risk of relapse and the relations with treatments.

Wang Y, Yin Q, Yu Q, Zhang J, Liu Z, Wang S, Lv S, Niu Y.

Breast Cancer Res Treat. 2011 Nov;130(2):489-98. doi: 10.1007/s10549-011-1709-6. Epub 2011 Aug 12.

PMID:
21837481
4.

Invasive breast cancer: a significant correlation between histological types and molecular subgroups.

Caldarella A, Buzzoni C, Crocetti E, Bianchi S, Vezzosi V, Apicella P, Biancalani M, Giannini A, Urso C, Zolfanelli F, Paci E.

J Cancer Res Clin Oncol. 2013 Apr;139(4):617-23. doi: 10.1007/s00432-012-1365-1. Epub 2012 Dec 27.

PMID:
23269487
5.

Female breast cancer status according to ER, PR and HER2 expression: a population based analysis.

Caldarella A, Crocetti E, Bianchi S, Vezzosi V, Urso C, Biancalani M, Zappa M.

Pathol Oncol Res. 2011 Sep;17(3):753-8. doi: 10.1007/s12253-011-9381-z. Epub 2011 Apr 10.

PMID:
21479875
6.

[Clinical characteristics and survival in the operable breast cancer patients with different molecular subtypes].

Zhang HM, Zhang BN, Xuan LX, Zhao P.

Zhonghua Zhong Liu Za Zhi. 2009 Jun;31(6):447-51. Chinese.

PMID:
19950556
7.

Apoptosis-, proliferation, immune function-, and drug resistance- related genes in ER positive, HER2 positive and triple negative breast cancer.

Kolacinska A, Chalubinska J, Zawlik I, Szymanska B, Borowska-Garganisz E, Nowik M, Fendler W, Kubiak R, Pawlowska Z, Morawiec Z, Szemraj J.

Neoplasma. 2012;59(4):424-32. doi: 10.4149/neo_2012_055.

PMID:
22489698
8.

Distribution of molecular breast cancer subtypes among Algerian women and correlation with clinical and tumor characteristics: a population-based study.

Cherbal F, Gaceb H, Mehemmai C, Saiah I, Bakour R, Rouis AO, Boualga K, Benbrahim W, Mahfouf H.

Breast Dis. 2015;35(2):95-102. doi: 10.3233/BD-150398.

PMID:
25736840
9.

Coordinated expression of ER, PR and HER2 define different prognostic subtypes among poorly differentiated breast carcinomas.

Fernandes RC, Bevilacqua JL, Soares IC, Siqueira SA, Pires L, Hegg R, Carvalho FM.

Histopathology. 2009 Sep;55(3):346-52. doi: 10.1111/j.1365-2559.2009.03380.x.

PMID:
19723150
10.

Prognostic value of circulating tumor cells according to immunohistochemically defined molecular subtypes in advanced breast cancer.

Munzone E, Botteri E, Sandri MT, Esposito A, Adamoli L, Zorzino L, Sciandivasci A, Cassatella MC, Rotmensz N, Aurilio G, Curigliano G, Goldhirsch A, Nolè F.

Clin Breast Cancer. 2012 Oct;12(5):340-6. doi: 10.1016/j.clbc.2012.07.001.

PMID:
23040002
11.

Variations in tumor marker levels in metastatic breast cancer patients according to tumor subtypes.

Kos T, Aksoy S, Sendur MA, Arik Z, Civelek B, Kandemir N, Ozdemir NY, Zengin N, Altundag K.

J BUON. 2013 Jul-Sep;18(3):608-13.

PMID:
24065471
12.
13.

[Clinical features and prognosis analysis of different breast cancer molecular subtypes].

Yang Q, Chen J, Li HJ, Yu M, Tian CX, Lü Q.

Zhonghua Zhong Liu Za Zhi. 2011 Jan;33(1):42-6. Chinese.

PMID:
21575463
14.
15.

Clinical characteristics and survival analysis of breast cancer molecular subtypes with hepatic metastases.

Ge QD, Lv N, Kong YN, Xie XH, He N, Xie XM, Wei WD.

Asian Pac J Cancer Prev. 2012;13(10):5081-6.

16.

Molecular breast cancer subtypes in premenopausal and postmenopausal African-American women: age-specific prevalence and survival.

Ihemelandu CU, Leffall LD Jr, Dewitty RL, Naab TJ, Mezghebe HM, Makambi KH, Adams-Campbell L, Frederick WA.

J Surg Res. 2007 Nov;143(1):109-18.

PMID:
17950079
17.

Hormone receptor and HER2 status in patients with breast cancer by races in southeastern Turkey.

Kuzhan A, Adli M, Eryigit Alkis H, Caglayan D.

J BUON. 2013 Jul-Sep;18(3):619-22.

PMID:
24065473
18.

A study of high-nuclear-grade breast cancer in Thailand: subclassification and correlation with prognostic factors and immunohistochemical study.

Chaiwun B, Nakrungsee S, Sukhamwang N, Srisukho S.

Breast Cancer. 2010;17(1):35-41. doi: 10.1007/s12282-009-0174-0.

PMID:
19789946
19.

Immunohistochemical analysis of ER, PR, Her2 and CK5/6 in infiltrative breast carcinomas in Indian patients.

Munjal K, Ambaye A, Evans MF, Mitchell J, Nandedkar S, Cooper K.

Asian Pac J Cancer Prev. 2009;10(5):773-8.

20.

FOXA1 expression in breast cancer--correlation with luminal subtype A and survival.

Badve S, Turbin D, Thorat MA, Morimiya A, Nielsen TO, Perou CM, Dunn S, Huntsman DG, Nakshatri H.

Clin Cancer Res. 2007 Aug 1;13(15 Pt 1):4415-21.

Items per page

Supplemental Content

Write to the Help Desk